Advertisement


Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Advertisement